HCA HCA Healthcare, Inc. Common Stock
Sobre HCA Healthcare, Inc. Common Stock Visão geral da empresa da Wikipedia
HCA Healthcare, Inc. is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
Ler mais
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was serving as chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
HCA Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
HCA Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
| Data ex | Valor |
|---|---|
| 16 de Junho de 2026 | $0,7800 |
| 17 de Março de 2026 | $0,7800 |
| 15 de Dezembro de 2025 | $0,7200 |
| 16 de Setembro de 2025 | $0,7200 |
| 16 de Junho de 2025 | $0,7200 |
| 17 de Março de 2025 | $0,7200 |
| 13 de Dezembro de 2024 | $0,6600 |
| 16 de Setembro de 2024 | $0,6600 |
| 14 de Junho de 2024 | $0,6600 |
| 14 de Março de 2024 | $0,6600 |
| 13 de Dezembro de 2023 | $0,6000 |
| 14 de Setembro de 2023 | $0,6000 |
| 15 de Junho de 2023 | $0,6000 |
| 16 de Março de 2023 | $0,6000 |
| 13 de Dezembro de 2022 | $0,5600 |
| 15 de Setembro de 2022 | $0,5600 |
| 15 de Junho de 2022 | $0,5600 |
| 16 de Março de 2022 | $0,5600 |
| 13 de Dezembro de 2021 | $0,4800 |
| 15 de Setembro de 2021 | $0,4800 |
HCA Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 6 20,0%
- Compra 11 36,7%
- Manter 12 40,0%
- Venda 1 3,3%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
21 analistas · 2026-08-17Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $7.62 | $7.54 | 0.08% |
| 31 de Março de 2026 | $7.15 | $7.21 | -0.06% |
| 31 de Dezembro de 2025 | $8.14 | $7.53 | 0.61% |
| 30 de Setembro de 2025 | $6.96 | $5.77 | 1.2% |
| 30 de Junho de 2025 | $6.83 | $6.31 | 0.52% |
| 31 de Março de 2025 | $6.45 | $5.84 | 0.61% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | — |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | — |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | — |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | — |
| UHS | — | 9.4 | 9.7% | 8.6% | 21.4% | — |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | — |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | — |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | — |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 12
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
Balanço Patrimonial 22
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
Fluxo de Caixa 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
Lucratividade 5
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
Eficiência 2
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
Taxas de Crescimento 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
Demonstração de Resultados 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | -482,587,000 | 232,891,000 | 239,173,000 | 246,936,000 | -523,751,000 | 256,763,000 | 261,156,000 | 264,435,000 | -550,173,000 | 271,173,000 | 274,494,000 | 276,910,000 | -590,583,000 | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | -488,037,000 | 236,181,000 | 241,911,000 | 249,440,000 | -530,198,000 | 259,917,000 | 264,071,000 | 268,016,000 | -558,171,000 | 275,424,000 | 278,198,000 | 280,961,000 | -598,621,000 | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
Balanço Patrimonial 20
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
Fluxo de Caixa 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
Eficiência 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Avaliação (TTM) 14
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $77.11B | $75.20B | · | $73.57B | $71.91B | $70.64B | · | $68.53B | $66.91B | $65.00B | · | $62.64B | $61.24B | $60.33B | · | $60.01B | |
| Net Income TTM | $6.62B | $6.53B | · | $6.18B | $5.99B | $5.93B | · | $5.40B | $5.32B | $5.23B | · | $4.77B | $4.84B | $4.92B | · | $5.83B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.7 | 17.3 | · | 17.0 | 16.2 | 15.2 | · | 20.1 | 16.3 | 17.6 | · | 14.5 | 17.9 | 15.7 | · | 9.7 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.3 | 1.2 | · | 1.5 | 1.2 | 1.4 | · | 1.1 | 1.4 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| P / FCF | · | 117.7 | · | · | · | 127.2 | · | · | · | 65.0 | · | · | · | 120.1 | · | · | |
| EV / EBITDA | 135.0 | 154.7 | · | 152.3 | 149.4 | 148.2 | · | 170.5 | 150.6 | 159.4 | · | 136.0 | 158.5 | 146.5 | · | 118.7 | |
| EV / FCF | · | 160.7 | · | · | · | 193.1 | · | · | · | 93.8 | · | · | · | 182.8 | · | · | |
| EV / Revenue | 1.7 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Earnings Yield | 7.3% | 5.8% | · | 5.9% | 6.2% | 6.6% | · | 5.0% | 6.1% | 5.7% | · | 6.9% | 5.6% | 6.4% | · | 10.3% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Lucro líquido | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| EPS Diluído | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| Índice de liquidez corrente | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| Índice de Liquidez Seca | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Últimas notícias Notícias recentes mencionando esta empresa
- Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
- HCA Healthcare (HCA) Reports Q1 2026 Financial Growth With $19.1B in Revenue
- Atividade Notável de Opções na Quinta-feira: HCA, HRTG, ZM
- Estratégia de Financiamento da HCA Healthcare (HCA) se Expande – Veja Como
- HCA Healthcare supera estimativas de lucro trimestral com demanda por cuidados médicos
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 1.486 declarantes · $39.4B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 128 (-51 vs trimestre anterior) | 174 (+70 vs trimestre anterior) | 450 (-30 vs trimestre anterior) | 555 (-4 vs trimestre anterior) | +16.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6.118.113.464 | 13.104.814 | 15,52% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.954.150.533 | 10.141.708 | 10,03% | Ações |
| Sanders Capital, LLC | $3.442.060.818 | 8.828.287 | 8,73% | Ações |
| STATE STREET CORP | $2.912.102.056 | 7.469.035 | 7,39% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $1.750.298.867 | 4.489.212 | 4,44% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $1.225.259.672 | 3.159.159 | 3,11% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.057.704.509 | 2.712.828 | 2,68% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861.456.107 | 2.209.485 | 2,19% | Ações |
| NORGES BANK | $836.457.140 | 2.145.367 | 2,12% | Ações |
| Capital World Investors | $770.864.224 | 1.977.121 | 1,96% | Ações |
| Capital International Investors | $747.403.041 | 1.916.947 | 1,90% | Ações |
| Crake Asset Management LLP | $449.072.183 | 1.151.792 | 1,14% | Ações |
| Metropolis Capital Ltd | $430.915.307 | 910.564 | 1,09% | Ações |
| Darsana Capital Partners LP | $428.879.000 | 1.100.000 | 1,09% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414.533.777 | 1.063.207 | 1,05% | Ações |
| Life Cycle Investment Partners Ltd | $355.737.196 | 912.404 | 0,90% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $339.685.814 | 871.235 | 0,86% | Ações |
| FMR LLC | $325.199.295 | 834.080 | 0,83% | Ações |
| BARCLAYS PLC | $299.888.573 | 769.162 | 0,76% | Ações |
| LYRICAL ASSET MANAGEMENT LP | $255.015.742 | 654.071 | 0,65% | Ações |
| BlackRock, Inc. | $240.062.291 | 615.718 | 0,61% | Ações |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235.649.908 | 604.401 | 0,60% | Ações |
| National Pension Service | $230.650.346 | 591.578 | 0,59% | Ações |
| NORDEA INVESTMENT MANAGEMENT AB | $230.189.125 | 594.466 | 0,58% | Ações |
| GOLDMAN SACHS GROUP INC | $209.775.669 | 538.038 | 0,53% | Ações |
| Gobi Capital LLC | $195.742.325 | 502.045 | 0,50% | Ações |
| Cryder Capital Partners LLP | $194.561.738 | 499.017 | 0,49% | Ações |
| Swiss National Bank | $172.097.446 | 441.400 | 0,44% | Ações |
| AustralianSuper Pty Ltd | $159.635.782 | 409.438 | 0,41% | Ações |
| Consulta Ltd | $155.956.000 | 400.000 | 0,40% | Ações |
| LEE DANNER & BASS INC | $152.150.679 | 390.240 | 0,39% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $151.472.265 | 388.500 | 0,38% | Opção de compra |
| Mitsubishi UFJ Asset Management Co., Ltd. | $147.943.761 | 379.450 | 0,38% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $139.697.405 | 358.300 | 0,35% | Ações |
| Vanguard Global Advisers, LLC | $136.962.509 | 351.285 | 0,35% | Ações |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $134.838.505 | 288.820 | 0,34% | Ações |
| ALLIANCEBERNSTEIN L.P. | $134.459.788 | 284.126 | 0,34% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $132.794.974 | 340.596 | 0,34% | Ações |
| TD Asset Management Inc | $131.847.152 | 338.165 | 0,33% | Ações |
| Legal & General Group Plc | $127.805.162 | 327.798 | 0,32% | Ações |
| California Public Employees Retirement System | $124.133.958 | 318.382 | 0,31% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $120.619.879 | 309.369 | 0,31% | Ações |
| JANE STREET GROUP, LLC | $119.540.274 | 306.600 | 0,30% | Opção de compra |
| VANGUARD ASSET MANAGEMENT, Ltd | $116.069.863 | 297.699 | 0,29% | Ações |
| CAPTRUST FINANCIAL ADVISORS | $114.741.071 | 294.291 | 0,29% | Ações |
| ANTIPODES PARTNERS Ltd | $113.045.096 | 289.941 | 0,29% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $109.718.328 | 231.845 | 0,28% | Ações |
| CITADEL ADVISORS LLC | $105.660.190 | 271.000 | 0,27% | Opção de compra |
| RHUMBLINE ADVISERS | $97.580.413 | 250.277 | 0,25% | Ações |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $97.026.076 | 248.855 | 0,25% | Ações |
| MACKENZIE FINANCIAL CORP | $93.597.383 | 240.061 | 0,24% | Ações |
| BloombergSen Inc. | $93.160.317 | 238.940 | 0,24% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $92.247.974 | 236.600 | 0,23% | Opção de venda |
| Brandywine Global Investment Management, LLC | $89.380.814 | 191.451 | 0,23% | Ações |
| BANK OF AMERICA CORP /DE/ | $89.069.981 | 228.449 | 0,23% | Ações |
| NEUBERGER BERMAN GROUP LLC | $85.926.216 | 220.386 | 0,22% | Ações |
| MILFORD FUNDS LTD | $82.165.029 | 210.739 | 0,21% | Ações |
| Bridgewater Associates, LP | $79.227.208 | 203.204 | 0,20% | Ações |
| Prana Capital Management, LP | $75.552.494 | 193.779 | 0,19% | Ações |
| DANSKE BANK A/S | $73.238.497 | 187.844 | 0,19% | Ações |
| FRANKLIN RESOURCES INC | $70.965.828 | 182.015 | 0,18% | Ações |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $70.445.715 | 180.681 | 0,18% | Ações |
| Quantinno Capital Management LP | $70.407.055 | 180.581 | 0,18% | Ações |
| ARGENT CAPITAL MANAGEMENT LLC | $69.149.681 | 177.357 | 0,18% | Ações |
| Retirement Systems of Alabama | $68.081.812 | 174.618 | 0,17% | Ações |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $66.167.842 | 169.709 | 0,17% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $64.793.090 | 166.183 | 0,16% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $64.665.206 | 165.855 | 0,16% | Ações |
| HSBC HOLDINGS PLC | $64.431.534 | 165.332 | 0,16% | Ações |
| AVIVA PLC | $64.264.789 | 164.828 | 0,16% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $64.194.533 | 135.649 | 0,16% | Ações |
| SEB Asset Management AB | $63.257.255 | 162.244 | 0,16% | Ações |
| TODD ASSET MANAGEMENT LLC | $62.567.208 | 160.474 | 0,16% | Ações |
| Swedbank AB | $62.528.998 | 160.376 | 0,16% | Ações |
| W1M Investment Management Ltd | $61.247.490 | 143.647 | 0,16% | Ações |
| HARRIS ASSOCIATES L P | $60.080.879 | 154.097 | 0,15% | Ações |
| Ensign Peak Advisors, Inc | $58.372.381 | 149.715 | 0,15% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $57.747.778 | 148.113 | 0,15% | Ações |
| CITADEL ADVISORS LLC | $57.235.852 | 146.800 | 0,15% | Opção de venda |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57.160.993 | 146.800 | 0,15% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $56.512.217 | 144.944 | 0,14% | Ações |
| Pictet Asset Management Holding SA | $52.147.803 | 133.739 | 0,13% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $50.752.761 | 130.172 | 0,13% | Ações |
| Pentwater Capital Management LP | $50.685.700 | 130.000 | 0,13% | Ações |
| D. E. Shaw & Co., Inc. | $50.554.307 | 129.663 | 0,13% | Ações |
| APG Asset Management N.V. | $50.368.550 | 147.699 | 0,13% | Ações |
| AMF Tjanstepension AB | $50.355.853 | 129.154 | 0,13% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $50.349.225 | 129.137 | 0,13% | Ações |
| EQUITABLE TRUST CO | $49.147.974 | 126.056 | 0,12% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $48.919.124 | 125.469 | 0,12% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $48.197.812 | 123.619 | 0,12% | Ações |
| AMERICAN CENTURY COMPANIES INC | $47.460.140 | 121.727 | 0,12% | Ações |
| OpenArc Corporate Advisory, LLC | $47.210.610 | 121.087 | 0,12% | Ações |
| L1 Capital International Pty Ltd | $46.121.648 | 118.294 | 0,12% | Ações |
| FIRST TRUST ADVISORS LP | $44.251.579 | 113.498 | 0,11% | Ações |
| PFA Pension, Forsikringsaktieselskab | $44.046.098 | 112.971 | 0,11% | Ações |
| United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund | $43.830.264 | 112.417 | 0,11% | Ações |
| EP Wealth Advisors, LLC | $43.287.826 | 111.026 | 0,11% | Ações |
| WOLVERINE TRADING, LLC | $42.597.104 | 101.200 | 0,11% | Opção de compra |
| MERCER GLOBAL ADVISORS INC /ADV | $42.302.070 | 108.497 | 0,11% | Ações |
Executivos da empresa 91 insiders · 54 diretores · 31 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 de Fevereiro de 2026 F | 64.842 | 0 | 7 | $-21.483.290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 de Fevereiro de 2013 A | 21.429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 de Maio de 2026 G | 46.576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 de Fevereiro de 2024 F | 22.251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 de Novembro de 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 de Novembro de 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 de Novembro de 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 de Julho de 2005 F | 13.865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 de Novembro de 2024 M | 6.843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 de Julho de 2024 M | 27.008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 de Fevereiro de 2024 F | 17.936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 de Novembro de 2022 M | 202.443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 de Novembro de 2022 S | 30.807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 de Dezembro de 2012 A | 335.657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 de Novembro de 2011 M | 144.714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 de Julho de 2006 A | 62.173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 de Outubro de 2005 A | 26.154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 de Outubro de 2004 D | 9.029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 de Maio de 2004 D | 24.177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 de Fevereiro de 2026 F | 23.062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 13 de Fevereiro de 2026 M | 8.853 | 0 | 2 | $-2.747.520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 de Fevereiro de 2026 S | 11.993 | 0 | 2 | $-4.126.932 |
| Christopher F. Wyatt | SVP & Controller | 11 de Fevereiro de 2026 S | 44.379 | 0 | 1 | $-2.020.000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 de Fevereiro de 2026 F | 10.407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 de Fevereiro de 2026 F | 32.080 | 0 | 1 | $-747.135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 de Fevereiro de 2025 F | 11.113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 de Novembro de 2024 S | 9.454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 de Novembro de 2024 M | 52.702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 de Agosto de 2024 G | 18.526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 de Julho de 2024 S | 3.510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 de Julho de 2024 S | 17.755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 de Maio de 2024 S | 5.185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 de Março de 2024 M | 1.576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 de Abril de 2023 M | 24.643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 de Novembro de 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 de Maio de 2021 S | 50.062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 de Fevereiro de 2021 F | 5.578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 de Fevereiro de 2021 F | 10.122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 de Maio de 2019 A | 194.145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 de Fevereiro de 2019 M | 84.157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 de Fevereiro de 2019 M | 881.823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 de Fevereiro de 2018 M | 7.003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 de Fevereiro de 2018 M | 35.546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 de Fevereiro de 2018 M | 65.199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 de Maio de 2017 M | 26.378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 de Novembro de 2016 M | 110.167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 de Fevereiro de 2016 A | 51.965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 de Maio de 2012 M | 299.030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 de Outubro de 2009 A | 188.340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 de Fevereiro de 2009 M | 13.092 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 4 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 de Fevereiro de 2026 | 31,60% | Declaração inicial | — | SEC |
| 22 de Novembro de 2006 | — | Declaração inicial | — | SEC | |
| Merrill Lynch Bank USA | 11 de Setembro de 2006 | — | Declaração inicial | — | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 de Agosto de 2006 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 207 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IHF · iShares Trust | 4,67% | 141.320 SH | 8 de Agosto de 2026 | Diário |
| BUL · Pacer Funds Trust | 3,91% | 11.437 NS | 30 de Abril de 2026 | N-PORT |
| YALL · Tidal Trust I | 3,61% | 9.261 NS | 31 de Maio de 2026 | N-PORT |
| BWTG · ETF Opportunities Trust | 3,02% | 1.646 NS | 31 de Maio de 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,32% | 99.335 SH | 8 de Agosto de 2026 | Diário |
| ABIG · EA Series Trust | 2,00% | 2.938 NS | 29 de Maio de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,99% | 39.985 NS | 30 de Abril de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,67% | 31.685 SH | 8 de Agosto de 2026 | Diário |
| COWZ · Pacer Funds Trust | 1,64% | 688.264 NS | 30 de Abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,64% | 1.762 NS | 30 de Abril de 2026 | N-PORT |
| FEGE · RBB Fund Trust | 1,46% | 74.706 NS | 31 de Maio de 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,39% | 60.385 SH | 8 de Agosto de 2026 | Diário |
| RPG · Invesco Exchange-Traded Fund Trust | 1,30% | 63.448 SH | 8 de Agosto de 2026 | Diário |
| TMFE · RBB Fund, Inc. | 1,29% | 2.892 NS | 31 de Maio de 2026 | N-PORT |
| AMID · EA Series Trust | 1,23% | 3.402 NS | 29 de Maio de 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,15% | 7.180 NS | 30 de Abril de 2026 | N-PORT |
| FMAG · FIDELITY COVINGTON TRUST | 1,12% | 6.544 NS | 30 de Abril de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,12% | 73.639 NS | 30 de Abril de 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,10% | 4.883 NS | 30 de Abril de 2026 | N-PORT |
| IYH · iShares Trust | 0,99% | 89.420 SH | 8 de Agosto de 2026 | Diário |
| NEAR · iShares U.S. ETF Trust | 0,99% | 48.109.000 SH | 8 de Agosto de 2026 | Diário |
| CURE · Direxion Shares ETF Trust | 0,98% | 3.122 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470.451 SH | 8 de Agosto de 2026 | Diário |
| NFRA · FlexShares Trust | 0,88% | 62.176 NS | 30 de Abril de 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0,87% | 5.693 NS | 30 de Abril de 2026 | N-PORT |
| RXL · ProShares Trust | 0,86% | 1.632 NS | 31 de Maio de 2026 | N-PORT |
| DIVB · iShares Trust | 0,85% | 36.806 SH | 8 de Agosto de 2026 | Diário |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,82% | 24.078.000 | 8 de Agosto de 2026 | Diário |
| LSEQ · Harbor ETF Trust | 0,81% | 285 NS | 30 de Abril de 2026 | N-PORT |
| IXJ · iShares Trust | 0,80% | 81.465 SH | 8 de Agosto de 2026 | Diário |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,76% | 26.493.000 | 8 de Agosto de 2026 | Diário |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,74% | 2.335 SH | 8 de Agosto de 2026 | Diário |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,73% | 21.329 NS | 30 de Abril de 2026 | N-PORT |
| RFFC · ALPS ETF Trust | 0,68% | 533 NS | 31 de Maio de 2026 | N-PORT |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,68% | 2.698 NS | 30 de Abril de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12.075 SH | 8 de Agosto de 2026 | Diário |
| VCEB · VANGUARD WORLD FUND | 0,62% | 8.146.000 PA | 8 de Agosto de 2026 | Diário |
| FDMO · FIDELITY COVINGTON TRUST | 0,61% | 11.771 NS | 30 de Abril de 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,58% | 72.768 NS | 30 de Abril de 2026 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund VI… | 0,56% | 9.664 NS | 31 de Maio de 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11.876 SH | 8 de Agosto de 2026 | Diário |
| VLLU · Harbor ETF Trust | 0,54% | 54 NS | 30 de Abril de 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,53% | 7.404 NS | 30 de Abril de 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,51% | 844 NS | 30 de Abril de 2026 | N-PORT |
| VALQ · AMERICAN CENTURY ETF TRUST | 0,50% | 4.620 NS | 31 de Maio de 2026 | N-PORT |
| AKAF · ETF Series Solutions | 0,50% | 39 NS | 31 de Maio de 2026 | N-PORT |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22.679.000 | 8 de Agosto de 2026 | Diário |
| ROUS · Lattice Strategies Trust | 0,47% | 6.388 NS | 30 de Abril de 2026 | N-PORT |
| VCLT · VANGUARD SCOTTSDALE FUNDS | 0,46% | 54.218.000 PA | 8 de Agosto de 2026 | Diário |
| CGGR · Capital Group Growth ETF | 0,45% | 290.273 NS | 31 de Maio de 2026 | N-PORT |